StockData
Caribou Biosciences, Inc. logo

Caribou Biosciences, Inc. (CRBU) company profile

CRBUNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 5, 2026Score 9/3074% below fair value
$0.34−0.01 (-3.43%)

Close on Nov 17, 2026Market cap $36.53MP/E –Yield –

About Caribou Biosciences

Biological Products, (No Diagnostic Substances), SIC 2836

Caribou Biosciences is a clinical-stage biopharmaceutical company focused on developing genome-edited cell therapies for patients with devastating diseases. Utilizing its proprietary CRISPR hybrid RNA-DNA (chRDNA) technology, the company engineers allogeneic, off-the-shelf chimeric antigen receptor (CAR)-T cell therapies designed to enhance precision and overcome the limitations of autologous cell therapies. Its clinical development pipeline features product candidates targeting hematologic malignancies, primarily vispacabtagene regedleucel (vispa-cel) for relapsed or refractory B cell non-Hodgkin lymphoma and CB-011 for relapsed or refractory multiple myeloma. The therapies are aimed at patients suffering from severe blood cancers who require accessible and prompt cellular interventions.

The company conducts clinical trials across multiple countries, having evaluated its programs in medical centers within the United States, Australia, and Israel. Product manufacturing is conducted through contract manufacturing organizations. While specific administrative headquarters are not stated in the provided text, its operational footprint includes clinical study locations spanning North America, the Middle East, and Oceania.

Summary of the business section of Caribou Biosciences's latest annual report, written by StockData.

Company profile

Company

Legal name
Caribou Biosciences, Inc.
Founded
2011
Headquarters
Berkeley, CA
Address
2929 7th Street, Suite 105 94710
Phone
(510) 982-6030
Employees
97, Dec 31, 2025
Industry
Biological Products, (No Diagnostic Substances)
Incorporated in
Delaware
Fiscal year ends
December 31
Auditor
Deloitte & Touche LLP, San Francisco, California

Stock & identifiers

Ticker
CRBU
Exchange
Nasdaq
IPO date
Jul 23, 2021
Shares outstanding
107M, Aug 7, 2026
Public float
$112.50M, Jun 30, 2025
Filer category
<br>Emerging growth company
SEC CIK
1619856
CUSIP
142038108
ISIN
US1420381089
FIGI
BBG008G28LJ5
Share class FIGI
BBG008G28LH7
EIN
45-3728228

Executives and directors

Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years

NamePositionShares owned
Rachel E. HaurwitzPresident and CEO, Director3,816,545
Timothy P. KellyChief Technology Officer73,125
Barbara G. McClungChief Legal Officer481,564
Tina M. AlbertsonChief Medical Officer68,523
Ruhi Ahmad KhanChief Business Officer104,998
Sriram RyaliChief Financial Officer72,360
Steven KannerChief Scientific Officer431,556
Ryan FischesserVP of Finance and Controller118,854
Natalie SacksDirector–
Ran ZhengDirector–
Nancy WhitingDirector–
Dara Richardson-HeronDirector–
Scott BraunsteinDirector–
David Lee JohnsonDirector–
Andrew GuggenhimeDirector–

Executive compensation, fiscal 2025

Summary compensation table from the latest proxy statement

ExecutiveSalaryBonusStock awardsOption awardsOtherTotalvs. prior year
Rachel Haurwitz
President and chief executive officer
$667.53K$312.07K$192.82K$654.54K$14.00K$1.84M-56%
Sriram Ryali
Chief financial officer
$483.16K$164.90K–$367.35K$14.00K$1.03M–
Barbara McClung
Chief legal officer
$502.03K$170.69K$52.88K$179.98K$14.00K$919.57K-43%

Stock and option awards are grant-date fair values, not realized pay. “Other” includes pension value changes and all other compensation. Source proxy statement.

IPO

From the final prospectus (Form 424B4) and the first day of trading

Offering

Type
Initial public offering
Final prospectus filed
Jul 23, 2021
Offer price
$16.00
Securities offered
19,000,000
Gross proceeds
$304.00M
Exchange
Nasdaq
First trading day
Jul 23, 2021
First-day close
$16.32+2.0%
Lock-up ends (est.)
Jan 19, 2022

“Per Share Total Public offering price $ 16.00 $ 304,000,000 Underwriting discount (1) $ 1.12 $ 21,280,000 Proceeds, before expenses, to us $ 14.88 $ 282,720,000 (1) We refer you to “Underwriting” beginning on page 219 of this prospectus for additional information regarding underwriting compensation.”

Lock-up end is estimated as 180 days after the first trading day; the prospectus sets the actual terms.

Employees

Headcount reported in annual reports

“As of February 27, 2026, we had 97 total employees, all of whom were full-time.”

Corporate history

Events identified from SEC filings

See a number that looks wrong?